About Philip Saylor, MD

Clinical Interests:



55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-5130
Fax: 617-643-2690

Medical Education

  • MD, University of Pittsburgh School of Medicine
  • Residency, UC San Diego Medical Center
  • Residency, UCSD Medical Center
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, Dana-Farber/Partners CancerCare
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    Select Publications:

    • Saylor, P.J., R.J. Lee, K.S. Arora, V. Deshpande, R. Hu, K. Olivier, E. Meneely, M.N. Rivera, D.T. Ting, C.L. Wu, and D.T. Miyamoto, Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer. Clin Cancer Res, 2016. PMID: 27440270.
    • Singh, H., Y. Liu, X. Xiao, L. Lin, J. Kim, P. Van Hummelen, C.L. Wu, A.J. Bass, and P.J. Saylor, Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget, 2016. PMID: 27078850.
    • Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). J Clin Oncol. 2014 Apr 10;32(11): 1143-50. PMID: 24590644.
    • Lee R, Saylor P, Michaelson M, Rothenberg S, Smas M, Miyamoto D, Gurski C, Xie W, Maheswaran S, Haber D, Goldin J, Smith M. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 1;19(11): 3088-94. PMID 23553848.
    • Saylor P, Smith M, O'Malley A, Keating N. Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer. Eur Urol. 2014 Mar; 65(3): 642-9. PMID: 23428068.